HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008).

AbstractOBJECTIVE:
To determine the response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell multicentric or thymic lymphoma.
DESIGN:
Retrospective case series.
ANIMALS:
41 client-owned dogs with lymphoma.
PROCEDURES:
Medical records of dogs in which lymphoma was diagnosed between February 2006 and October 2008 were reviewed. Entry criteria included that dogs had a confirmed lymphoma that was immunophenotyped to be of B-cell or T-cell origin. Only dogs that received doxorubicin alone as their first chemotherapy treatment and were evaluated 1 week later were included in the study. Dogs were excluded when they had received prior treatment with corticosteroids. Medical records were reviewed to obtain signalment, stage and substage of lymphoma, and immunophenotype and to determine whether the dog had hypercalcemia at the time of diagnosis.
RESULTS:
Dogs with T-cell lymphoma had a significantly lower response rate to doxorubicin than did dogs with B-cell lymphoma. Twenty-five of 29 (86.2%) dogs with B-cell lymphoma had a complete response, compared with 2 of 12 dogs in the T-cell group that had a complete response. The overall response rate of dogs with B-cell lymphoma was 100%, compared with a response rate of 50% in dogs with T-cell lymphoma.
CONCLUSIONS AND CLINICAL RELEVANCE:
Standard-of-care chemotherapy protocols for the treatment of dogs with lymphoma include doxorubicin. Many dogs with T-cell lymphoma did not respond to doxorubicin; therefore, multiagent protocols containing doxorubicin may not be optimal. Alternative protocols should be considered for dogs with T-cell lymphoma that do not respond to doxorubicin.
AuthorsLynda M Beaver, Gabriele Strottner, Mary K Klein
JournalJournal of the American Veterinary Medical Association (J Am Vet Med Assoc) Vol. 237 Issue 9 Pg. 1052-5 (Nov 01 2010) ISSN: 0003-1488 [Print] United States
PMID21034344 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Doxorubicin
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Dog Diseases (drug therapy)
  • Dogs
  • Doxorubicin (administration & dosage, therapeutic use)
  • Female
  • Lymphoma, B-Cell (drug therapy, veterinary)
  • Lymphoma, T-Cell (drug therapy, veterinary)
  • Male
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: